An observational study in Biliary Tract Cancer and Cholangiocarcinoma, sponsored by CHA University. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by CHA University · Observational
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Biliary Tract Neoplasms with a site in Korea, Republic of — 27 open to participants now, 40 under way, 9 of them phase 3. Biliary Tract Neoplasms · Korea, Republic of.
Among the 96 studies in Biliary Tract Neoplasms with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2024, is one of 11 observational ones, reaches primary completion later than 14 of the 39 other live ones, and was the 85th registered.
521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.
Browse Biliary Tract Neoplasms studies →27 of the 96 studies in Biliary Tract Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
SK Life Science, Inc. · Sites in Korea, Republic of, United States
Ages 18+
Taiho Pharmaceutical Co., Ltd. · Sites in Korea, Republic of, Australia, Japan and 1 more country
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Australia and 16 more countries
Ages 18+
Aichi Medical University · Sites in Korea, Republic of, Japan
Ages 18+
CHA University · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 61 · Phase 3 12 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 160 across 73 observational studies indexed under Biliary Tract Neoplasms.
Median enrollment 127 across the 85 interventional studies, 100 across the 11 observational. Of the 42 that completed or were terminated, 12 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 96 have an industry lead sponsor. The 10 most frequent:
CHA University is the lead sponsor of 54 studies on the registry; 17 are open to participants now.
CHA University has 6 studies filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Biliary Tract Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05784688TiumBio Co., Ltd.Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | 2026-12 |
| NCT07142226CHA UniversityRole of ctDNA in Genetic Profiling & Outcomes for Advanced BTC | 2026-12-31 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 10 to your calendar (.ics) → With an account.
Among the 96 studies in Biliary Tract Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.
Biliary tract cancers (BTCs) have a higher prevalence in Asia compared to Western countries, with South Korea ranking second globally in BTC incidence. According to data from the Central Cancer Registry in 2023, the 5-year survival rate for BTC from 2017 to 2021 was 28.9%, significantly lower than other cancers such as gastric cancer (77.9%), colorectal cancer (74.3%), and breast cancer (93.8%).
Surgery is the primary treatment for BTC, but only 40-50% of patients are eligible for curative resection. For patients with unresectable, advanced, or metastatic BTC, the standard first-line treatment has been gemcitabine plus cisplatin (GP) since the results of the ABC-02 Phase 3 trial in 2010. Recently, two Phase 3 trials-TOPAZ-1 in 2022 and KEYNOTE-966 in 2023-demonstrated significant survival benefits with the addition of immune checkpoint inhibitors (durvalumab or pembrolizumab) to GP therapy, establishing these combination regimens as the new first-line standard treatment for advanced BTC. These combinations have been approved for use in South Korea.
However, for patients who fail first-line GP therapy, the most commonly selected second-line treatment, FOLFOX (5-FU + leucovorin + oxaliplatin), offers only a modest survival extension of about one month compared to supportive care. This highlights the clinical unmet need for more effective second-line treatments. A multicenter Phase 2 trial has demonstrated the efficacy of lenvatinib plus pembrolizumab as a promising treatment option for these patients.
This prospective observational study aims to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in real-world clinical practice for advanced BTC. Additionally, the study seeks to explore potential predictive biomarkers through genetic analyses of blood and tissue samples to better understand which patients are most likely to benefit from this treatment.
Patients with Advenced Biliary Tract Cancer will be recruited at CHA Bundang Medical Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lenvatinib plus pembrolizumab combination therapy.
Drug: lenvatinib plus pembrolizumab
Drug pages: LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
* The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times): * Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2) * (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time). * Additional tumor tissue samples will be collected only if possible, according to the following schedule: If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens).
Also known as: Liquid biopsy, RNA-sequencing, NGS
collected tumor samples
Tumor samples will be collected from patients with advanced biliary tract cancer. The incidence of genetic alterations in these samples will be analyzed using H\&E staining, immunohistochemistry (IHC), and RNA sequencing. The data will be reported as the percentage of patients with detectable genetic alterations and correlated with treatment response and survival duration.
Time frame: through study competition, an average of 2 years
Collected Blood Samples
Blood samples will be collected from patients with advanced biliary tract cancer.These samples will undergo flow cytometry, ELISA, and ctDNA analysis, and the results will be correlated with treatment response and survival outcomes. (PFS, OS).
Time frame: Through study completion, an average of 2 years
Multi-Omics Analysis for Therapeutic Target Identification
Multi-omics analysis, including DNA, RNA, and protein analysis, will be conducted to identify potential therapeutic targets and subtypes of biliary tract cancer. The analysis will integrate molecular data to identify actionable genetic alterations and protein expression levels, which will be summarized and correlated with clinical outcomes (e.g., PFS, OS).
Time frame: Through study completion, an average of 2 years.
Biomarkers on the Efficacy of Lenvatinib and Pembrolizumab for Advanced Biliary Tract Cancer
his outcome will investigate the correlation between molecular biomarkers and the efficacy of lenvatinib and pembrolizumab in patients with advanced biliary tract cancer. Biomarkers will be evaluated for their association with overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). The outcome will report which biomarkers predict better therapeutic response.
Time frame: Through study completion, an average of 2 years.
Progression-Free Survival (PFS)
This outcome measures the time from the start of treatment to the first occurrence of disease progression or death. PFS will be analyzed using Kaplan-Meier survival curves, and the median PFS will be reported.
Time frame: Through study completion, an average of 2 years.
Overall Survival (OS)
This outcome measures the time from the start of treatment to death from any cause. OS will be evaluated and reported using Kaplan-Meier survival analysis, and median OS will be calculated.
Time frame: Through study completion, an average of 2 years.
Objective Response Rate (ORR)
ORR is defined as the percentage of patients who achieve a complete or partial response based on RECIST 1.1 criteria. This outcome will report the proportion of patients who show a measurable response to treatment.
Time frame: Through study completion, an average of 2 years.
Incidence of Adverse Events (AEs)
The safety and tolerability of lenvatinib and pembrolizumab will be assessed by monitoring the occurrence and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Time frame: Through study completion, an average of 2 years.
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.
Of 44 observational studies under Biliary Tract Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 132. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHA University